Related Experiment Video
Updated: Nov 2, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.1K
Icodec Advances the Prospect of Once-Weekly Insulin Injection
Richard D DiMarchi1, John P Mayer2
1Department of Chemistry, Indiana University, 800 East Kirkwood, Bloomington, Indiana 47405, United States.
Journal of Medicinal Chemistry
|June 16, 2021
Summary
Once-weekly insulin icodec offers a new option for basal glucose control. This ultralong-acting insulin provides a less burdensome, safe, and effective alternative to daily injections.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Basal glucose control typically requires daily insulin administration via injection or pump.
- Current basal insulin therapies necessitate frequent dosing for maintaining glycemic targets.
Discussion:
- Insulin icodec, an ultralong-acting basal insulin analog, demonstrates the feasibility of a once-weekly injection regimen.
- This novel formulation simplifies treatment protocols for patients requiring basal insulin support.
Key Insights:
- Once-weekly insulin icodec is non-inferior to once-daily basal insulin treatments in terms of safety and efficacy.
- The simplified dosing schedule of insulin icodec may improve patient adherence and reduce treatment burden.
Outlook:
- Further research will explore long-term outcomes and patient-reported benefits of weekly insulin icodec.
- Insulin icodec represents a significant advancement in basal insulin therapy, potentially enhancing diabetes management.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
346
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
346
01:16Insulin: Dosing Regimen and Adverse Effects
343
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
343
01:25Insulin: Biosynthesis, Chemistry, and Preparation
726
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
726
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
70
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
70
01:15Diabetes: Management and Pharmacotherapy
648
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
648
01:28Insulin: The Receptor and Signaling Pathways
1.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.8K